echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Everything can be connected!

    Everything can be connected!

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 2, 2021, Acepodia announced the completion of a $109 million Series C financing


    Acepodia is developing a pipeline of ACE therapies using its ACC technology to couple tumor-targeting antibodies to immune cells, such as natural killer (NK) cells or γδ T cells


    ▲Antibody-coupled cell technology (Image source: Acepodia's official website)

    Its lead product, the potential "first-in-class" investigational therapy ACE1702, is an antibody-conjugated cell therapy generated by coupling a monoclonal antibody targeting HER2 to the surface of allogeneic NK cells


    In addition, it is worth mentioning that WuXi Junuo has reached an agreement with Acepodia in 2020 to obtain exclusive priority authorization for the clinical and commercialization of ACE1702 in mainland China, Hong Kong and Macau


    References:

    [1] Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.